AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Propanc Biopharma shares surge 31.99% intraday after filing provisional patents for resistant cancer and fibrosis treatments.
ByAinvest
Monday, Dec 1, 2025 12:41 pm ET1min read
Propanc Biopharma surged 31.99% intraday after announcing the submission of two provisional patents for novel treatments targeting resistant cancer and fibrosis, filed via its Australian subsidiary. The patents, developed through joint research with Spanish universities, mark the first expansion of its lead product, PRP, into fibrosis, a high-unmet-need chronic condition. CEO James Nathanielsz highlighted the patents as a “significant turning point,” with a planned 2026 Phase 1b First-In-Human study to define PRP’s therapeutic dose. The news underscores Propanc’s potential to commercialize PRP across multiple disease areas, positioning it as a non-cytotoxic therapy addressing both oncology and fibrotic disorders. The filing also signals global IP strategy, with plans to pursue patents in key jurisdictions, enhancing long-term commercial prospects.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet